NMRA
Neumora Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.31
−2.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 5.0M | 5.0M | — | 668.0K | — |
| Gross Profit | (5.0M) | (5.0M) | — | (668.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 153.1M | 176.1M | 200.9M | 142.7M | 104.7M |
| SG&A Expense | 53.2M | 60.1M | 62.5M | 44.8M | 31.1M |
| General & Admin Expense | 53.2M | 60.1M | 62.5M | 45.5M | 31.1M |
| Selling & Marketing Expense | — | — | — | (668.0K) | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 206.2M | 236.2M | 263.5M | 187.5M | 135.9M |
| Cost and Expenses | 211.2M | 241.2M | 263.5M | 188.2M | 135.9M |
| Operating Income (EBIT) | (211.2M) | (241.2M) | (263.5M) | (188.2M) | (135.9M) |
| Non-Operating | |||||
| Interest Income | 5.2M | 8.3M | 19.9M | 16.6M | 4.6M |
| Interest Expense | 6.5M | 3.2M | — | — | — |
| Net Interest Income | (1.3M) | 5.1M | 19.9M | 16.6M | 4.6M |
| Other Non-Op Income/Expense | (1.5M) | 4.4M | 19.9M | (47.5M) | 5.0M |
| Non-Operating Income (excl Interest) | (4.1M) | (7.6M) | (19.9M) | 47.5M | (5.0M) |
| EBT (Pre-Tax Income) | (212.7M) | (236.8M) | (243.6M) | (235.7M) | (130.9M) |
| Income Tax Expense | 30.0K | 130.0K | 178.0K | 268.0K | — |
| Bottom Line | |||||
| Net Income | (212.7M) | (236.9M) | (243.8M) | (235.9M) | (130.9M) |
| Earnings from Cont. Ops | (212.7M) | (236.9M) | (243.8M) | (235.9M) | (130.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (212.7M) | (236.9M) | (243.8M) | (235.9M) | (130.9M) |
| Per Share | |||||
| Basic EPS | ($1.23) | ($1.45) | ($1.53) | ($1.49) | ($0.86) |
| Diluted EPS | ($1.23) | ($1.45) | ($1.53) | ($1.49) | ($0.86) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 185.2M | 163.4M | 159.4M | 158.8M | 151.9M |
| Diluted Shares Outstanding | 185.2M | 163.4M | 159.4M | 158.8M | 151.9M |
| Profitability Metrics | |||||
| EBITDA | (207.1M) | (233.4M) | (243.0M) | (235.0M) | (130.3M) |
| D&A | 40.0K | 208.0K | 631.0K | 668.0K | 594.0K |
| EBIT | (207.2M) | (233.6M) | (243.6M) | (235.7M) | (130.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026